ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2434

Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response

Mikhail Volkov, Arieke Kampstra, Karin van Schie, Joanneke Kwekkeboom, Arnoud de Ru, Peter van Veelen, Thomas Huizinga, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands

Meeting: ACR Convergence 2023

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), Autoantibody(ies), microbiome, Mouse Models, RA, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: RA – Etiology & Pathogenesis

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Gut-residing bacteria, such as E.coli, can acetylate their proteome under conditions of amine starvation. It is postulated that the (gut) microbiome is involved in the breach of immune tolerance to modified self-proteins leading to the anti-modified protein antibodies (AMPA), hallmarking seropositive RA. Our aim was to determine whether acetylated bacterial proteins can induce AMPA-responses cross-reactive to modified self-proteins and be recognized by human AMPA (hAMPA).

Methods: E. coli-bacteria were grown under amine starvation to generate endogenously acetylated bacterial proteins. Furthermore, E. coli proteins were acetylated chemically (Figure 1A). Recognition of these proteins by hAMPA was analysed by western blotting and ELISA; recognition by B cells carrying a modified protein-reactive B cell receptor (BCR) was analysed with a pSyk activation assay. C57BL/6 mice were immunized with (modified) bacterial protein fractions, and sera were analysed by ELISA (Figure 2A).

Results: Chemically modified bacterial protein fractions contained high levels of acetylated proteins (Figure 1B) and were readily recognized by hAMPA (Figure 1C) and able to activate B cells carrying modified protein-reactive BCRs (Figure 1E-F). Likewise, although expressing lower levels of acetylation, also endogenously acetylated protein fractions were recognized by hAMPA in ELISA (Figure 1D). Immunizing mice with chemically modifed protein fractions induced a strong cross-reactive AMPA response, targeting various modified antigens including citrullinated proteins (Figure 2B-C). Interestingly, highly acetylated bacterial proteins could induce an AMPA response even without an adjuvant (Figure 2D).

Conclusion: Acetylated bacterial proteins are recognizable by hAMPA and capable of inducing a cross-reactive AMPA response in mice. These observations provide first evidence for a novel mechanism, involving the (endogenous) acetylation of the bacterial proteome, allowing a breach of tolerance to modified proteins and the formation of cross-reactive AMPA.

Supporting image 1

Figure 1. Recognition of acetylated bacterial antigens by hAMPA
(A) Schematic overview of the generation of NBP, EABP and CABP. (B) Western blotting with NBP, EABP and CABP stained with anti-acetyllysine polyclonal rabbit antibody. (C) Western blotting with NBP, EABP and CABP stained with hAMPA mAbs, recognizing acetylated proteins: 7E4 IgG and 1E3 IgM. (D) ELISA with 1E3 IgM, 7E4 IgG and polyclonal IgG from an RA patient serum isolated with CAcP4 peptide. (E) pSyk MFI, visualizing BCR activation of Ramos B cells expressing 7E4 IgG after incubation with acetylated E. coli antigens. (F) Summary of three BCR activation experiments with 7E4 Ramos B cells. Statistical differences are indicated with asterisks, indicating p-value: * < 0.05, ** < 0.01, **** < 0.0001.

Supporting image 2

Figure 2. Immunization of mice with bacterial acetylation proteins
(A) Immunization scheme of the performed mouse experiments. (B) Reactivity of titrated mouse serum to modified and unmodified versions of fibrinogen, per immunizing antigen. (C) Mice immunized with the antigens with the adjuvant: titers at OD = 0.1, as determined by ELISA to modified and native versions of fibrinogen. (D) Mice immunized with CABP or AcOVA without the adjuvant: reactivity of individual mouse serum samples to modified and unmodified versions of fibrinogen. Statistical differences are indicated with asterisks, indicating p-value: * < 0.05, ** < 0.01, **** < 0.0001.
A-C: data are representative of two experiments. AcOVA: acetylated ovalbumin, CABP: chemically acetylated bacterial proteins; EABP: endogenously acetylated bacterial proteins; NBP: non-acetylated bacterial proteins; PBS: phosphate buffer saline.


Disclosures: M. Volkov: Pfizer, 3, 11; A. Kampstra: None; K. van Schie: None; J. Kwekkeboom: None; A. de Ru: None; P. van Veelen: None; T. Huizinga: None; R. Toes: Bristol-Myers Squibb(BMS), 5; D. van der Woude: None.

To cite this abstract in AMA style:

Volkov M, Kampstra A, van Schie K, Kwekkeboom J, de Ru A, van Veelen P, Huizinga T, Toes R, van der Woude D. Acetylated Bacterial Proteins as Potent Antigens Inducing an Anti-modified Protein Antibody Response [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/acetylated-bacterial-proteins-as-potent-antigens-inducing-an-anti-modified-protein-antibody-response/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acetylated-bacterial-proteins-as-potent-antigens-inducing-an-anti-modified-protein-antibody-response/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology